Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA
Retrieved on:
Monday, August 31, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Programmed cell death, Cell signaling, Proteins, Pharmaceuticals policy, Cell biology, Inhibitor of apoptosis, Orphan drug, Cellular Inhibitor of Apoptosis Protein 1, Apoptosis, XIAP, Tolinapant (ASTX660), T-Cell Lymphomas, Astex Pharmaceuticals, Inc.
Orphan drug designation is granted to drugs intended to treat a rare disease or condition.
Key Points:
- Orphan drug designation is granted to drugs intended to treat a rare disease or condition.
- The designation provides for seven years of marketing exclusivity in the US following product approval, as well as certain tax incentives and grants.
- Astexs development of tolinapant is aimed at bringing a new therapeutic option for patients with this type of cancer.
- Tolinapant is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP).